Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pioglitazone [111025-46-8]
Cat# T0214-50mg
Size : 50mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Pioglitazone
Catalog No. T0214 CAS 111025-46-8
Synonyms: U 72107
Pioglitazone (U 72107) is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Pioglitazone has been linked to rare instances of acute liver injury.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Pioglitazone, CAS 111025-46-8
| Description | Pioglitazone (U 72107) is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Pioglitazone has been linked to rare instances of acute liver injury. |
| Targets&IC50 | PPARγ (mouse):0.99 μM (EC50), PPARγ (human):0.93 μM (EC50) |
| In vitro | In mouse models of Parkinson's disease (PD) using MPTP, Pioglitazone reduces activation of microglia, inducible nitric oxide synthase (iNOS) positive cells, and glial fibrillary acidic protein (GFAP) positive cells in the striatum and substantia nigra pars compacta. Administering approximately 20 mg/kg of Pioglitazone daily attenuates MPTP-induced neuroglial activation and prevents the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Additionally, in 10-month-old APPV717I transgenic mice, Pioglitazone decreases the number of activated microglia and reactive astrocytes in the hippocampus and cortex. Pioglitazone also reduces mRNA and protein levels of beta-secretase-1 (BACE1), as well as the levels of soluble Abeta1-42 peptide. |
| In vivo | Pioglitazone is primarily metabolized by CYP2C8, with secondary metabolism by CYP3A4. |
| Synonyms | U 72107 |
| Molecular Weight | 356.44 |
| Formula | C19H20N2O3S |
| CAS No. | 111025-46-8 |
Storage
Solubility Information
DMSO: 15 mg/mL (42.08 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
References and Literature
1. Jaakkola T, et al. Basic Clin Pharmacol Toxicol,2006, 99(1), 44-51. 2. Shiomi T, et al. Circulation,2002, 106(24), 3126-3132. 3. Dehmer T, et al. J Neurochem,2004, 88(2), 494-501. 4. Breidert T, et al. J Neurochem,2002, 82(3), 615-624. 5. Heneka MT, et al. Brain,2005, 128(Pt 6), 1442-1453. 6. Fang J, Zhang P, Wang Q, et al. Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer's Disease[J]. medRxiv. 2020, 12(2): 025032.
Citations
1. Zhan Z T, Liu L, Cheng M Z, et al. The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment. Journal of Immunology Research. 2022 2. Qi Y, Hu M, Qiu Y, et al.Mitoglitazone ameliorates renal ischemia/reperfusion injury by inhibiting ferroptosis via targeting mitoNEET.Toxicology and Applied Pharmacology.2023: 116440. 3. Schöckel L, Woischke C, Surendran S A, et al.PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil.BMC cancer.2024, 24(1): 1-12. 4. Huang Q, Ru Y, Luo Y, et al.Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases.Science Advances.2024, 10(13): eadk1200.